Clinical trials for cellular therapy products: conclusions reached by foreign regulatory bodies

Currently, the problem of adopting viable human cell-based drugs – biomedical cell products (BCPs) – in medical practice in the Russian Federation includes, among others, lack of experience in clinical trials for such drugs and insufficient expert assessment under the national state registration procedure. In global practice, by the beginning of 2020, there were over 30 cellular therapy products (human cellular- and tissue-based products) known to have undergone clinical trials for sales licenses from regulatory bodies in the United States, European Union, Japan, and South Korea. Most cellular therapy products are intended for treatment of severe orphan diseases and lifethreatening conditions that currently cannot be treated by traditional drugs or methods. The aim of this study is to analyze the global experience in clinical trials for cellular therapy products and also to examine conclusions reached by regulatory authorities with regards to issuance of sales licenses for the products. Particular attention was paid to clinical trials that subsequently led to granting of sales license (state registration). In reviewing such trials, we also focused on the types and number of clinical trials, the number of patients involved in the clinical trials, conclusions made by expert regulatory agencies on the efficacy, safety and risk/benefit ratio. Most of the products were approved for use based on uncontrolled phase II clinical trials. In the clinical trial, apart from the historical group and the placebo-controlled group, there was also a control group that received nothing. The number of patients in most clinical trials was limited, especially for drugs intended for treatment of rare genetic diseases, as well as drugs approved for use in Japan.

biomedical cell product, human cellular- and tissue-based products, cell therapy, clinical trials, regulatory findings

1. State register of drugs [Internet]. Available from: https://grls.rosminzdrav.ru/Default.aspx.

2. Summary Basis for Regulatory Action: KYMRIAH, ALL [Internet]. – Food and Drug Administration, 2017. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM577221.pdf.

3. Summary basis for regulatory action – YESCARTA, DLBCL [Internet]. – Food and Drug Administration, 2017. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM584335.pdf.

4. Assessment report. Kymriah (EMA/462626/2018) [Internet]. – European Medicines Agency, 2018. Available from: https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf.

5. Assessment report. Yescarta (EMA/CHMP/481168/2018) [Internet]. – European Medicines Agency, 2018. Available from: https://www.ema.europa.eu/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf.

6. Summary Basis for Regulatory Action – KYMRIAH, DLBCL [Internet]. – Food and Drug Administration; 2018. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606836.pdf.

7. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Tmeny M et al. Outcomes of diffuse large Bcell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone marrow transplantation. 2017; 52 (2): 216–221. doi: 10.1038/bmt.2016.213.

8. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Tmeny M et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone marrow transplantation. 2016; 51 (1): 51–57. doi: 10.1038/bmt.2015.213.

9. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. The lancet oncology. 2019; 20 (1): 31–42. doi: 10.1016/S1470-2045(18)30864-7.

10. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130 (16): 1800–1808. doi: 10.1182/blood-2017-03-769620.

11. EPAR summary for the public. Holoclar (EMA/6865/2015) [Internet]. – European Medicines Agency, 2015. Available from: https://www.ema.europa.eu/documents/overview/holoclar-epar-summary-public_en.pdf.

12. Summary of product characteristics. Holoclar [Internet]. – European Medicines Agency. Available from: https://www.ema.europa.eu/documents/product-information/holoclar-epar-product-information_en.pdf.

13. Assessment report. Zalmoxis (EMA/ CHMP/589978/2016) [Internet]. – European Medicines Agency, 2016. Available from: https://www.ema.europa.eu/documents/assessment-report/zalmoxis-epar-publicassessment-report_en.pdf.

14. McBlane JW. Preclinical safety evaluation [Internet]. – 2016. Available from: http://www.pmda.go.jp/files/000211287.pdf.

15. Summary of the risk management plan (RMP) for Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) (EMA/26006/2015) [Internet]. – European Medicines Agency, 2015. Available from: https://www.ema.europa.eu/documents/rmpsummary/holoclar-epar-risk-management-plan-summary_en.pdf.

16. Detela G, Lodge A. EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorization. Mol Ther Methods Clin Dev. 2019;13: 205–232. doi: 10.1016/j.omtm.2019.01.010.

17. EPAR summary for the public. Zalmoxis (EMA/454627/2016) [Internet]. – European Medicines Agency, 2016. Available from: https://www.ema.europa.eu/documents/overview/zalmoxis-epar-summary-public_en.pdf.

18. Summary of product characteristics. Alofisel [Internet]. – European Medicines Agency. Available from: https://www.ema.europa.eu/documents/product-information/ alofisel-epar-product-information_en.pdf.

19. Assessment report. Alofisel (EMA/CHMP/64055/2018) [Internet]. – European Medicines Agency, 2018. Available from: https://www.ema.europa.eu/documents/assessment-report/alofisel-epar-public-assessment-report_en.pdf.

20. EPAR summary for the public. Alofisel (darvadstrocel) (EMA/1380/2018) [Электронный ресурс]. – European Medicines Agency, 2017. Available from: https://www.ema.europa.eu/documents/overview/alofisel-epar-summary-public_en.pdf.

21. Summary of product characteristics. Spherox [Internet]. – European Medicines Agency. Available from: https://www.ema.europa.eu/documents/product-information/spherox-epar-product-information_en.pdf .

22. EPAR summary for the public. Spherox (EMA/326337/2017) Spherox [Internet]. – European Medicines Agency, 2017. Available from: https://www.ema.europa.eu/documents/overview/spherox-epar-summary-public_en.pdf.

23. Summary of risk management plan for Spherox (spheroids of human autologous matrix-associated chondrocytes) [Internet]. – European Medicines Agency. Available from: https://www.ema.europa.eu/documents/rmp-summary/spherox-epar-risk-management-plan-summary_en.pdf.

24. Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012; 120 (17): 3615–3624. doi: 10.1182/blood-2011-12-396879.

25. EPAR summary for the public. Strimvelis (EMA/ CHMP/249031/2016) [Internet]. – European Medicines Agency, 2016. Available from: https://www.ema.europa.eu/documents/overview/strimvelis-epar-summary-public_en.pdf.

26. Assessment report. Strimvelis (EMA/ CHMP/272303/2016 Rev 1) [Internet]. – European Medicines Agency, 2016. Available from: https://www. ema.europa.eu/documents/assessment-report/strimvelisepar-public-assessment-report_en.pdf.

27. Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016; 128 (1): 45–54. doi: 10.1182/blood-2016-01-688226.

28. Assessment report. Zynteglo. [Internet]. – European Medicines Agency, 2019. Available from: https://www.ema.europa.eu/en/documents/assessment-report/zyntegloepar-public-assessment-report_en.pdf.

29. Summary Basis for Regulatory Action. LAVIV® [Internet]. Available from: http://wayback.archive-it.org/7993/20170723023939/https:/www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM262780.pdf.

30. Fibrocell Science Inc [Internet]. Available from: http://www.annualreports.com/HostedData/AnnualReportArchive/f/NASDAQ_FCSC_2016.pdf.

31. Pharmaceutical administration and regulations in Japan [Internet]. – Japan Pharmaceutical Manufacturers Association, 2017. Available from: http://www.jpma.or.jp/english/parj/pdf/2017.pdf.

32. Report on the Deliberation Results. HeartSheet [Internet]. – 2015. Available from: http://www.pmda.go.jp/files/000215222.pdf.

33. Terumo [Internet] – Available from: http://www.terumo.com/.

34. Review Report. JACE [Internet]. – 2007. Available from: http://www.pmda.go.jp/files/000223079.pdf.

35. JACE. To all of our investors [Internet]. – 2013. Available from: http://www.jpte.co.jp/english/ir/messages/20130626.html.

36. Report on the Deliberation Results. JACE [Internet]. – 2016. Available from: http://www.pmda.go.jp/files/000223080.pdf.

37. Report on the Deliberation Results. Temcell [Internet]. – 2015. Available from: http://www.pmda.go.jp/files/000215658.pdf.

38. Osiris Therapeutics, Inc. [Internet]. Available from: http://www.osiris.com/.

39. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ et al. Adjuvant immunotherapy with autologous cytokineinduced killer cells for hepatocellular carcinoma. Gastroenterology. 2015; 148 (7): 1383–1391. doi: 10.1053/j.gastro.2015.02.055.

40. Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS et al. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean med sci. 2014; 29 (1): 23–31. doi: 10.3346/jkms.2014.29.1.23.